guided with experience

Gord has over 30 years financial services experience with his last role as President of Cidel Trust Company, a national trust company and asset management firm. Other senior roles with CIBC and RBC included senior leadership, corporate strategy, corporate services, governance, sales management, investment management, fiduciary services, philanthropic planning, cross border structuring, risk management and training and development.

As President of Cidel Trust, Gord lead the creation of a national trust company, was responsible for institutional asset management for Western Canada and also created a national indigenous strategy as well as building out strategic relationships with ATB and Richardson GMP. At RBC, Gord’s last role was Joint Head of the Caribbean (Barbados, Cayman and the Bahamas) for RBC International Wealth Management responsible for discretionary asset management, RBC Dominion Securities, global custody, captive insurance, and fund administration, as well as trust and corporate services based out of Barbados.

Gord serves on several for profit and not for profit boards and is a Chartered Financial Analyst (CFA), Trust and Estate Practitioner (TEP), Family Enterprise Advisor (FEA), and Corporate Director (ICD.D).

Gord is the Founder and CEO of Anchor Wealth Advisory, a consulting firm that focuses on governance and strategy for successful families. Gord also has a deep passion for Indigenous Economic Development.

Josh Lounsberry is a founder and executive with over a decade of experience operating in complex healthcare and technology environments. As the founding CEO of Lumiio, he led the development and commercialization of a platform connecting patient organizations, researchers, and life sciences partners. His work centers on identifying what limits progress in complex systems – aligning stakeholders, clarifying direction, and creating the conditions for teams and organizations to move forward with momentum. He has led initiatives spanning product development, commercialization, and global-scale partnerships, consistently working at the intersection of strategy, execution, and stakeholder alignment. Josh brings a systems-level perspective to leadership, with a particular strength in navigating ambiguity, building alignment across diverse groups, and translating complexity into practical action.

Blaine Penny is the CEO of Lumiio, and an engineer by training with 25+ years of leadership across health, technology, and engineering. He has built and scaled software, data, and services businesses from startup to global enterprise, including serving as Vice President at IHS Markit where he oversaw a $200M product portfolio and large multidisciplinary teams. Blaine’s governance experience includes co-founder and Director of the MitoCanada Foundation, former Board member of the Canadian Organization for Rare Disorders (CORD), Executive Advisor to the Mitochondrial Innovation Initiative (Mito2i) at the University of Toronto, former Board Chair of Intricate Group, and former Director and Officer of IHS Canada. A trusted partner to biopharma, patient organizations, and research networks globally, he is also a key architect of the Global FSHD Innovation Hub.

Lawrence is a clinician investigator at the University of Calgary where he conducts research in registry best practices at the Korngut Registry Science Lab. He led the development of the Canadian Neuromuscular Disease Registry which includes 31 participating clinics across Canada which has successfully recruited over 4500 patients across four disease sub registries. Recognizing the challenges of designing, implementing and operating registries in various disease groups he has focused much of his academic research on optimizing registry methodology for successful “real-world evidence” outcomes. He has published extensively on the science of registries including leading the Canadian Neurological Registry Best Practice Guidelines. He has also provided guidance and support for the development of registries and their integration into Health Communities, clinical trial programs and post-marketing studies since 2009.